This evidence brief summarises key issues and priorities for action in Europe and Central Asia on HIV testing. It is largely based on data collected in 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.
The use of pre-exposure prophylaxis (PrEP) as an HIV prevention strategy, particularly among men who have sex with men (MSM) as well as other population groups at higher risk of HIV infection, has been receiving more and more attention during 2014. Preliminary results of clinical trials and research studies suggest that it could be an effective HIV prevention tool for Europe.
Following an invitation from Greek authorities, a team of experts from ECDC, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the WHO Regional Office for Europe visited Greece in May 2012.
This review of scientific literature identified evidence for a number of strategies to overcome barriers to HIV testing. It highlights the need to expand testing across Europe and the necessity to ensure that HIV programmes are vigorously monitored and evaluated, both locally and nationally.
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries.
This report presents the situation of HIV testing in Europe and Central Asia. It summarises data on implementation of national guidelines that shape HIV testing policies, the provision and uptake of HIV testing services in general and among key populations, and efforts being made to widen engagement with HIV testing and reduce late diagnosis.
ECDC estimates that 810 000 people are currently living with HIV in the EU/EEA – of which 122 000 (15%) do not know they are infected. Early diagnosis helps to prevent further transmission and lowers the risk of severe health complications.